Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study.
Alessandro de SireAlessio BaricichFilippo RenòCarlo CisariNicola FuscoMarco InvernizziPublished in: Aging clinical and experimental research (2019)
Hip fractures are the most common osteoporotic fractures related to disability in older adults, requiring surgery and a subsequent rehabilitation treatment. Sarcopenia is currently considered as a predictive of worse outcome in hip fracture patients and myostatin has been recently proposed a potential biomarker of this condition. Twenty hip fracture patients after total hip replacement (mean aged 75.9 ± 2.4 years) were randomly divided into two groups of ten subjects (groups A and B). Both groups performed a rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol). Group A received also 2-month amino acid supplementation. Serum myostatin levels significantly decreased after 2 months in both group A (p = 0.01) and group B (p = 0.03) in sarcopenic patients only in group A (p = 0.04). These results suggest that myostatin might be considered a promising biomarker of sarcopenia in hip fracture older adults' patients undergoing rehabilitation and amino acid supplementation.
Keyphrases
- hip fracture
- end stage renal disease
- patients undergoing
- ejection fraction
- chronic kidney disease
- newly diagnosed
- amino acid
- physical activity
- peritoneal dialysis
- prognostic factors
- skeletal muscle
- total hip
- clinical trial
- minimally invasive
- multiple sclerosis
- patient reported outcomes
- total knee arthroplasty
- quality improvement
- acute coronary syndrome
- resistance training
- community dwelling
- double blind
- surgical site infection